Introduction
============

Vitiligo is a skin disease characterized by dysfunction or destruction of melanocytes with secondary depigmentation, which constitutes the pathophysiological hallmark of the disease. The pathogenesis of vitiligo involves multiple factors. In 1950, Lerner proposed the neural theory ([@b1-br-0-0-700]). Since then, different evolving theories for the pathogenesis of vitiligo have been mentioned, including susceptibility genes, autoimmune response, abnormalities in the melanocytes and/or cellular damage from oxidative stress.

Genes for generalized vitiligo (GV) include *XBP1*, *FOXP3*, *NALPq*, *TYR*, and *TLSP* ([@b2-br-0-0-700]). Additionally, certain MHC genes are also associated with vitiligo, including the *HLA-DRB1*\*07, *HLA-A2* and *HLA-B17* alleles. Similarly, SNAPs genotyping studies have demonstrated that the 6q27 chromosome is linked to this skin depigmentation disorder ([@b3-br-0-0-700]). The pathophysiology of autoimmune vitiligo involves humoral and cellular immunity by mechanisms that produce melanocyte damage. Clinically, depigmentation can be a unique symptom associated with autoantibody production and/or cell hypersensitivity. However, in a few cases of GV, the skin disease can be associated with other autoimmune diseases. With respect to the mechanisms involved in the autoimmune destruction of melanocytes, CD8 T cells appear to trigger melanocyte damage. Then, vitiligo antigens are released by cytolysis. Therefore, the initial insult is followed by a humoral autoimmune response against vitiligo-associated autoantigens, including MART-1, tyrosinase, and gp100 ([@b2-br-0-0-700]--[@b11-br-0-0-700]).

The epidemiology of this disease indicates that the prevalence of vitiligo ranges from 0.5 to 1% of the general population, and the disease is equally distributed in females and males ([@b12-br-0-0-700]). Considering that vitiligo is a common disease associated with various autoimmune diseases and that these comorbidities are usually evaluated as separate clinical entities, it is of interest to define the rheumatic comorbidities that can be associated with vitiligo as part of a multi-autoimmune syndrome, wherein this designation applies to the association of three or more autoimmune diseases in the same patient.

The aim of the present study was to determine the association of vitiligo with multiple autoimmune rheumatic diseases in a database covering a period of 10 years.

Materials and methods
=====================

### Subjects

The clinical files of patients who were treated in the Department of Rheumatology from 2005 and 2015 were reviewed. Using the data files, the main disease that led to the evaluation was identified. Subsequently, the number of patients with or without rheumatic autoimmune diseases such as osteoarthritis, lumbalgia or tendinitis associated with vitiligo was determined. Each patient was reviewed by a skilled rheumatologist and dermatologist, respectively, and clinical criteria for disease for classification in each autoimmune disease was followed. Additionally, in each patient with vitiligo, the availability of serum samples stored in a freezer was determined, allowing for evaluation of the anti-melanocyte and anti-tyrosinase antibodies, which are markers of autoimmune vitiligo. Additionally, a group of rheumatic patients lacking autoimmune disease was included as the control group. Autoimmune co-morbidities and autoantibodies were assessed in the two groups.

The study was approved by the ethics committee of Universidad Autónoma de Zacatecas (Zacatecas, Mexico). Patient consent was obtained from each patient.

### Anti-melanocyte antibodies

An intradermal nevus, \~0.5 cm in diameter, of the preauricular region in a patient who was 27 years with no clinical or serological manifestations of autoimmunity was removed for cosmetic reasons. Prior to this procedure, a signed authorization was obtained to use part of the nevus as an antigenic source. The lesion was divided into two parts; one part was sent for histopathological analysis and another part was used for indirect immunofluorescence studies ([@b13-br-0-0-700]). The tissue was transported to the laboratory on ice, and was subsequently embedded in Tissue-Tek OCT^®^ (Leica Biosystems, Nussloch, Germany) and frozen at −20°C. Tissue samples were cut at 4 µm using a cryostat (−20°C), and the slices were fixed on slides. The serum samples were tested at dilutions of 1:20 to 1:160, incubated with the antigenic source for 30 min in a moist chamber, and the slides were washed three times in phosphate-buffered saline (PBS) (pH 7.2). This step was followed by a 30-min incubation with polyvalent FITC-labelled rabbit anti-human antiserum (cat. no. F4637; 1:80; Sigma-Aldrich, St. Louis, MO, USA). After three additional PBS washes, the slides were mounted with glycerol-PBS (9:1), and two independent observers evaluated the samples using an Olympus B-Max BX-40 fluorescence microscope (Olympus, Tokyo, Japan) in a blinded manner.

### Anti-tyrosinase antibodies

The specificity of the sera to tyrosinase was evaluated in triplicate by ELISA as previously described ([@b14-br-0-0-700]) with modifications. Polystyrene plates were covered overnight with 10 µg of tyrosinase fragment 369--377 (cat. no. T8455; Sigma-Aldrich) dissolved in 70% ethanol. Uncovered sites were neutralized with 4% BSA. The serum samples were diluted 1:100 and applied into the microwells. They were then incubated for 2 h at room temperature. After 3 washes, the samples were incubated with secondary antibody goat anti-human IgG HRP (cat. no. sc-2453; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) for 1 h. After washing again, the colour reaction was developed with TMB in a 30-min incubation. The reaction was then stopped with 0.5 M sulfuric acid and the microplates were read at 450 nm using a microplate reader (Thermo Fisher Scientific, Inc., Shanghai, China).

### Other autoantibodies

Anti-thyroid antibodies on a commercial antigenic source, anti-nuclear antibodies in HEp-2 cells (Immuno Concepts, Inc., Sacramento, CA, USA) and anti-epithelial antibodies, using as antigen source cow nose, were evaluated with indirect immunofluorescence.

### Statistical analysis

The probability of the association between vitiligo and certain autoimmune rheumatic disease was calculated using the χ^2^ test. The relative risk and odds ratios (OR), with 95% of confidence intervals, were determined using the Prism software program (GraphPad Software, Inc., San Diego, CA, USA). P\<0.0001 was considered statistically significant.

Results
=======

### Clinical records

In 10 years, a total of 5,251 records were filed. Each record corresponded to one patient, and these patients were evaluated over multiple rheumatology consultations. From these, 2,824 files corresponded to patients with autoimmune disease (54%), while the remaining 2,427 (46%) had other rheumatic diseases, including degenerative, metabolic or other diseases. The most prevalent autoimmune disease was exhibited by rheumatoid arthritis (RA) patients who met the ACR/EULAR classification criteria ([@b15-br-0-0-700]), which accounted for 43% of autoimmune rheumatic diseases. This was followed by 26% with lupus erythematosus, which met the ACR revised criteria for SLE ([@b16-br-0-0-700]). Other diseases, such as scleroderma, accounted for a lower proportion of the cases (2.4%). Of the total number of autoimmune rheumatic diseases, 19 patients, 16 women and 3 men, with a mean age of 36 years, had GV ([@b17-br-0-0-700]), corresponding to 0.672% of the sample. Clinically, most of the patients had skin depigmentation distributed along the face, hands and trunk ([Fig. 1](#f1-br-0-0-700){ref-type="fig"}). In contrast to the control group, only one patient with osteoarthritis had localized spots of vitiligo, and the prevalence was 0.0412%. The differences between the two groups were significant (P\<0.0002) ([Fig. 1](#f1-br-0-0-700){ref-type="fig"}). Of note, the relative risk for developing vitiligo was significantly increased in patients who had an additional autoimmune comorbidity, such as celiac of 33% ([@b18-br-0-0-700]) or thyroid disease in 19% ([@b19-br-0-0-700]) ([Table I](#tI-br-0-0-700){ref-type="table"}).

### Autoantibodies

Ninety-two percent of the group with autoimmune rheumatic disease and associated vitiligo tested positive for anti-melanocyte antibodies. Therefore, fluorescence was observed in scattered melanocytes along the epidermis as well as in melanosomes and melanin granules for some patients. The antibody titres varied across the patients. By contrast, the anti-tyrosinase antibodies were positive in 84% of the patients ([Fig. 2](#f2-br-0-0-700){ref-type="fig"}).

Other shared autoantibodies included rheumatoid factor and anti-CCP, ANA, anti-thyroid and anti-epithelial antibodies although none of the patients had symptoms of pemphigus.

Discussion
==========

Vitiligo is a disease characterized by the loss of pigment-producing cells. The disease has psychological and social consequences, and in some cases it is caused by autoimmunity. The aim of the present study was to determine the prevalence of vitiligo associated with other autoimmune rheumatic diseases. The main results of the present study were as follows. First, the prevalence of vitiligo associated with autoimmune rheumatic disease was 0.672. Second, autoantibodies against vitiligo-associated antigens were present in the 92% of the autoimmune group. Third, RA and lupus were frequently associated with vitiligo, although the relative risk of vitiligo as an event occurring, measured the magnitude of association using the cumulative incidence, rather than the total number. This measure showed the relative risk of vitiligo in RA was not different than the prevalence reported in the general population. Notably, the vitiligo risk was markedly increased when the two diseases were associated with thyroid or celiac disease.

Vitiligo has been extensively studied. In 1979, Goudie *et al* ([@b20-br-0-0-700]) brought attention to the comorbidities of vitiligo, suggesting that this disease constituted a set of mosaic patches with distinctive shared characteristics of autoimmunity. Traditionally, vitiligo alone has been extensively studied worldwide, including in Latin America. The present study was performed in the mestizo population of a central region of Mexico. The mestizo population results from a mixture between Amerindian Caucasian and African genes ([@b21-br-0-0-700]). In Mexico, the prevalence of vitiligo in children has been estimated as 2.6% ([@b22-br-0-0-700]). The present study addresses the prevalence of vitiligo in adult patients with rheumatic disease, and the global prevalence of vitiligo detected in the present study was 0.380, which is lower than the 0.5--2% reported in the overall worldwide population by Krüger and Schallreuter ([@b23-br-0-0-700]). The differences with the present results can be explained by ethnic factors or different methodologies used in the patients included in each study. Of note, the prevalence of vitiligo is variable; for instance, the prevalence in the Korean population is 0.12% ([@b24-br-0-0-700]), while it is lower (0.093%) in a Chinese Shaanxi Province ([@b25-br-0-0-700]). In both instances, the prevalence in some Asiatic countries is lower than in the present study.

Concurrence of various autoimmune diseases in a single patient captured the attention of different clinical research groups, and diverse names have been given to these associated comorbidities, including polyautoimmunity, multiple autoimmunity, and shared autoimmunity ([@b26-br-0-0-700]--[@b30-br-0-0-700]). The autoimmune rheumatic comorbidities associated with vitiligo are variable, including RA and psoriasis ([@b31-br-0-0-700]--[@b33-br-0-0-700]). In the Middle Eastern population, the association of vitiligo with RA is related to the TNFα-308 A/G promoter ([@b34-br-0-0-700]), which probably reflects that this cytokine participates in melanocyte destruction. Sjögren disease has been reported to be associated with vitiligo ([@b35-br-0-0-700]). Other autoimmune comorbidities that accompany rheumatic diseases and vitiligo include pernicious anemia ([@b36-br-0-0-700]), Graves\' disease, autoimmune haemolytic anemia ([@b37-br-0-0-700]), thyroid and celiac disease and other pathologies ([@b38-br-0-0-700]--[@b42-br-0-0-700]). Common pathogenic mechanisms that are suggested to facilitate these comorbidities involve the protein tyrosine phosphatase non-receptor type 22 (*PTPN22*) gene, which seems to increase the susceptibility for one patient to have a cluster of different autoimmune diseases. This cluster includes type I diabetes, RA, autoimmune thrombocytopenia, inflammatory myopathies, Graves\' disease, SLE, ANCA-associated vasculitis, and Cohn\'s disease ([@b43-br-0-0-700]). On the other hand, HLA-DQ pleiotropic genes are also involved in the pathogenesis of multiple autoimmunity ([@b44-br-0-0-700]).

In conclusion, based on the results of this study, the association between vitiligo and one autoimmune rheumatic disease is relatively low, which is probably similar to the prevalence of vitiligo in the general population. Nevertheless, when this disease is associated with more than two autoimmune comorbidities, including thyroid or celiac disease, its relative risk is notably increased. In such a case, a multiple autoimmune syndrome should be suspected.

![The vitiligo prevalence in rheumatic diseases. (A) Total number of patients grouped into autoimmune and non-autoimmune rheumatic diseases. (B) Patients with autoimmune rheumatic diseases associated with vitiligo. (C) Hand from a patient with dermatomyositis, vitiligo and Crohn\'s disease (as shown in the intestinal histology). (D) Drawing shows the clinical overlap of vitiligo and the comorbidities in the present study. RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; PSS, progressive systemic sclerosis; AS, ankylosing spondylitis; DM, dermatomyositis.](br-05-02-0176-g00){#f1-br-0-0-700}

![Antibodies against vitiligo autoantigens. Superior panel, representative immunofluorescence antibodies against melanocytes. Inferior panel (left), a graph with the percentage of positivity of vitiligo autoantoibodies. Inferior panel (right), the ELISA graph for anti-thyrosinase antibodies.](br-05-02-0176-g01){#f2-br-0-0-700}

###### 

Relative risk for developing vitiligo.

  Disease                      No. of patients   Vitiligo   Prevalence   P-value   Relative risk   OR
  ---------------------------- ----------------- ---------- ------------ --------- --------------- ----------------------------------------------------
  NARD                         2,427               1        0.041                                  
  ARD                          2,829             19         0.672        0.0002    0.0612          0.0608
  RA                           1,899               6        0.315        0.0257    0.1304          0.1300
  SLE                            742               3        0.404        0.0148    0.1019          0.1015
  Sjögren                          91              1        1.098        0.0004    0.0374          0.0371
  PSS                              68              1        1.470        0.0001    0.0280          0.0276
  DM                               20              1        5.000        0.0001    0.0082          0.0078
  Tyroiditis + RA or SLE           21              4        19.047       0.0001    0.0021          0.0017^[a](#tfn2-br-0-0-700){ref-type="table-fn"}^
  Celiac disease + SLE or RA         6             2        33.333       0.0001    0.0012          0.0008^[a](#tfn2-br-0-0-700){ref-type="table-fn"}^
  AS + Crohn\'s disease              4             1        25.000       0.0001    0.0016          0.0012^[a](#tfn2-br-0-0-700){ref-type="table-fn"}^

OR, odds ratio; NARD, non-autoimmune rheumatic disease; ARD, autoimmune rheumatic disease; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; AS, ankylosing spondylitis.

Highly significant, P\<0.0001.
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